{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:36:18Z","timestamp":1791804978526,"version":"4.3.4"},"reference-count":58,"publisher":"Royal College of General Practitioners","issue":"769","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"accepted":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid use can heighten pain perception over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine whether the effectiveness of opioid analgesia diminishes with treatment duration in those with chronic low back pain or osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>Systematic review of randomised trials comparing opioids with placebo\/opioid-minimised pain management strategies in those with chronic low back pain or osteoarthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A random-effects meta-analysis using MEDLINE, Embase, CENTRAL, and Scopus databases was undertaken in January 2025. The primary outcome was attainment of clinically important pain relief (\u2018moderate\u2019 or \u226530% improvement). The secondary outcome was on-treatment pain (100-point scale). The primary analysis was difference in primary\/secondary outcomes across short-term (\u22644 weeks), intermediate-term (4\u201312 weeks), and long-term (\u226512 weeks) duration subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 27 trials were eligible for inclusion. Clinically important pain relief differed significantly between short-, intermediate-, and long-term treatment durations (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.05). Opioid recipients were more likely to be responders in short-term trials (eight trials, risk ratio [RR] 1.42, 95% confidence interval [CI] = 1.08 to 1.89, moderate-certainty evidence), but not in intermediate-term trials (three trials, RR 1.04, 95% CI = 0.84 to 1.30, low-certainty evidence), or long-term trials (nine trials, RR 0.91, 95% CI = 0.73 to 1.14, moderate-certainty evidence), which trended in favour of controls. The mean difference in pain scores failed to reach this review\u2019s definition of clinical significance (\u226510 points) for any timepoint, but was statistically significant in the short and intermediate term.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although opioids likely provide meaningful pain relief over short durations (\u22644 weeks), they appear to provide little or no benefit beyond placebo over longer periods, and may worsen pain control beyond 12 weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3399\/bjgp.2025.0705","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:25:13Z","timestamp":1778153113000},"page":"e634-e643","source":"Crossref","is-referenced-by-count":1,"title":["Impact of treatment duration on the effectiveness of opioid analgesia: a systematic review and meta-analysis"],"prefix":"10.3399","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-4601","authenticated-orcid":false,"given":"Liesbeth S","family":"Froentjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine AM","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-3850","authenticated-orcid":false,"given":"Rodger A","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareiz","family":"Morcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M","family":"Wedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-9392","authenticated-orcid":false,"given":"Christina S","family":"Korowynk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Kelmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah N","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7024-2158","authenticated-orcid":false,"given":"Scott R","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026073017254194000_76.769.e634.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-011817-044739"},{"key":"2026073017254194000_76.769.e634.2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06251-w"},{"key":"2026073017254194000_76.769.e634.3","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2017.1381663"},{"key":"2026073017254194000_76.769.e634.4","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00004"},{"key":"2026073017254194000_76.769.e634.5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2147\/JPR.S190161","article-title":"Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence","volume":"12","author":"Rinonapoli","year":"2019","journal-title":"J Pain Res"},{"key":"2026073017254194000_76.769.e634.6","unstructured":"Higgins J Thomas J Chandler J (2024) Cochrane handbook for systematic reviews of interventions, version 6.5. accessed. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current. 19 Jun 2026."},{"key":"2026073017254194000_76.769.e634.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026073017254194000_76.769.e634.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026073017254194000_76.769.e634.9","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001390"},{"issue":"11","key":"2026073017254194000_76.769.e634.10","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-160-11-201406030-01006","article-title":"In the clinic: low back pain","volume":"160","author":"Chou","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026073017254194000_76.769.e634.11","doi-asserted-by":"publisher","DOI":"10.2165\/11533440-000000000-00000"},{"issue":"3","key":"2026073017254194000_76.769.e634.12","first-page":"233","article-title":"A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome","volume":"20","author":"Baratta","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"2026073017254194000_76.769.e634.13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.sjpain.2010.05.035","article-title":"A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients na\u00efve to potent opioids","volume":"1","author":"Breivik","year":"2010","journal-title":"Scand J Pain"},{"key":"2026073017254194000_76.769.e634.14","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.497720"},{"key":"2026073017254194000_76.769.e634.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00383-4"},{"key":"2026073017254194000_76.769.e634.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.356"},{"issue":"9","key":"2026073017254194000_76.769.e634.17","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial","volume":"158","author":"Christoph","year":"2017","journal-title":"Pain"},{"key":"2026073017254194000_76.769.e634.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2012.02.028"},{"key":"2026073017254194000_76.769.e634.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.04.018"},{"key":"2026073017254194000_76.769.e634.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.02.009"},{"key":"2026073017254194000_76.769.e634.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.03.008"},{"key":"2026073017254194000_76.769.e634.22","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90028-C"},{"key":"2026073017254194000_76.769.e634.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0899"},{"key":"2026073017254194000_76.769.e634.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21884"},{"key":"2026073017254194000_76.769.e634.25","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000146215.86038.38"},{"key":"2026073017254194000_76.769.e634.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2005.00057.x"},{"key":"2026073017254194000_76.769.e634.27","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12807"},{"issue":"3","key":"2026073017254194000_76.769.e634.28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5055\/jom.2010.0017","article-title":"A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis","volume":"6","author":"Munera","year":"2010","journal-title":"J Opioid Manag"},{"key":"2026073017254194000_76.769.e634.29","unstructured":"Rauck R (2012) Fentanyl transdermal matrix patch ZR-02-01 to treat chronic, moderate to severe non-malignant pain. accessed. https:\/\/clinicaltrials.gov\/study\/NCT00126763 . 29 Jun 2026."},{"issue":"1","key":"2026073017254194000_76.769.e634.30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1533-2500.2012.00555.x","article-title":"Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS\u00ae hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Pract"},{"key":"2026073017254194000_76.769.e634.31","unstructured":"Berger B (2015) Efficacy and safety study evaluating ADL5859 and ADL5747 in participants with pain due to osteoarthritis of the knee. accessed. https:\/\/clinicaltrials.gov\/study\/NCT00979953 . 29 Jun 2026."},{"key":"2026073017254194000_76.769.e634.32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.sjpain.2017.07.004","article-title":"Quantitative sensory tests fairly reflect immediate effects of oxycodone in chronic low-back pain","volume":"17","author":"Schliessbach","year":"2017","journal-title":"Scand J Pain"},{"issue":"8","key":"2026073017254194000_76.769.e634.33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1080\/03007995.2017.1335189","article-title":"Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study","volume":"33","author":"Serrie","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2026073017254194000_76.769.e634.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.04.035"},{"key":"2026073017254194000_76.769.e634.35","article-title":"A phase IIIb, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of OROS hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee","volume":"2011","author":"Vojta\u0161\u0161\u00e1k","year":"2011","journal-title":"Pain Res Treat"},{"key":"2026073017254194000_76.769.e634.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.05.005"},{"key":"2026073017254194000_76.769.e634.37","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000139910.97211.37"},{"key":"2026073017254194000_76.769.e634.38","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2011.0062"},{"key":"2026073017254194000_76.769.e634.39","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.07.2179"},{"issue":"12","key":"2026073017254194000_76.769.e634.40","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/j.pain.0000000000000315","article-title":"A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of xtampza ER in patients with moderate-to-severe chronic low back pain","volume":"156","author":"Katz","year":"2015","journal-title":"Pain"},{"issue":"6","key":"2026073017254194000_76.769.e634.41","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/j.pain.0000000000001517","article-title":"SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain","volume":"160","author":"Markman","year":"2019","journal-title":"Pain"},{"key":"2026073017254194000_76.769.e634.42","unstructured":"Purdue Pharma LP (2012) Safety and efficacy of buprenorphine transdermal delivery system in subjects with moderate to severe osteoarthritis of hip or knee. accessed. https:\/\/clinicaltrials.gov\/study\/NCT00313846 . 29 Jun 2026."},{"key":"2026073017254194000_76.769.e634.43","unstructured":"Finn A (2017) Efficacy and safety study of buprenorphine HCl buccal film in subjects with low back pain. accessed. https:\/\/clinicaltrials.gov\/study\/NCT01256450 . 29 Jun 2026."},{"key":"2026073017254194000_76.769.e634.44","unstructured":"Purdue Pharma LP (2015) Efficacy and safety of oxycodone\/naloxone controlled-release tablets (OXN) compared to placebo in opioid-experienced subjects with moderate to severe chronic low back pain. accessed. https:\/\/clinicaltrials.gov\/study\/NCT01358526 . 7 Jul 2026."},{"key":"2026073017254194000_76.769.e634.45","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000230"},{"issue":"1","key":"2026073017254194000_76.769.e634.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00325481.2016.1128307","article-title":"Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain","volume":"128","author":"Rauck","year":"2016","journal-title":"Postgrad Med"},{"key":"2026073017254194000_76.769.e634.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.04.006"},{"key":"2026073017254194000_76.769.e634.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2018.09.019"},{"key":"2026073017254194000_76.769.e634.49","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu137"},{"issue":"10","key":"2026073017254194000_76.769.e634.50","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/acr.24363","article-title":"Is there any role for opioids in the management of knee and hip osteoarthritis? A systematic review and meta\u2010analysis","volume":"73","author":"Osani","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2026073017254194000_76.769.e634.51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ejp.1522","article-title":"Opioids for chronic osteoarthritis pain: an updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration","volume":"24","author":"Welsch","year":"2020","journal-title":"Eur J Pain"},{"key":"2026073017254194000_76.769.e634.52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1225"},{"key":"2026073017254194000_76.769.e634.53","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2017-098043"},{"key":"2026073017254194000_76.769.e634.54","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2017.2"},{"key":"2026073017254194000_76.769.e634.55","doi-asserted-by":"publisher","DOI":"10.1177\/08830738060210062101"},{"key":"2026073017254194000_76.769.e634.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.10.050"},{"key":"2026073017254194000_76.769.e634.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.027"},{"key":"2026073017254194000_76.769.e634.58","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/465281"}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2025.0705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:26:50Z","timestamp":1785457610000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2025.0705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":58,"journal-issue":{"issue":"769","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.3399\/BJGP.2025.0705"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2025.0705","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}